New myopia lenses work twice as fast in kids — and younger patients benefit most

A next-generation spectacle lens is making waves in childhood myopia management. Interim results from a randomized, double-masked clinical trial in China show that children wearing Essilor Stellest 2.0 lenses — featuring HALT Max technology — for just 6 months achieved myopia control comparable to 1 full year of wear with the original Stellest lens. The treatment response is "effectively twice as fast," according to the study's principal investigator.

Meanwhile, a separate U.S.-based study published in JAMA Ophthalmology confirmed that the original Essilor Stellest lens maintains its myopia-slowing effect over 2 years of wear. The benefit was most pronounced in younger children, reinforcing the case for early intervention in myopia management.

By the Numbers

• 0.51 D lower myopia progression and 0.21 mm less axial elongation with Stellest 2.0 at 6 months vs. single-vision lenses
• 0.64 D lower myopia progression and 0.24 mm less axial elongation with original Stellest at 2 years
• Children aged 6–8 years saw 1.03 D lower progression — an 87% reduction — vs. single-vision wearers

Why it matters

Myopia rates are rising globally, and high myopia carries serious long-term risks like retinal detachment and vision loss. These findings suggest that spectacle-based interventions can actively slow disease progression — not just correct it — and that starting early makes a meaningful difference. For eye care professionals, this adds a noninvasive, familiar tool to the childhood myopia management toolkit.